- 1 Hydroxychloroquine plus azithromycin: a potential interest in reducing in-
- 2 hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?
- Benjamin Davido<sup>1,§</sup>, Thibaud Lansaman<sup>2</sup>, Simon Bessis<sup>1</sup>, Christine Lawrence<sup>3</sup>, Jean-
- 4 Claude Alvarez<sup>4</sup>, Hélène Mascitti<sup>1</sup>, Frédérique Bouchand<sup>5</sup>, Pierre Moine<sup>6</sup>, Véronique
- 5 Perronne<sup>1</sup>, Aurélie Le Gal<sup>1</sup>, Djillali Annane<sup>6</sup>, Christian Perronne<sup>1</sup>, Pierre De Truchis<sup>1,§</sup>,
- on behalf of the COVID-19 RPC Team\*
- <sup>1</sup> Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
- 8 Garches, France
- <sup>9</sup> Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond
- 10 Poincaré, Garches, France
- <sup>3</sup> EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France
- <sup>4</sup> Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
- 13 Garches, France
- <sup>5</sup> Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond
- 15 Poincaré, Garches, France
- <sup>6</sup> Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
- 17 Garches, France

- 18 §: Both authors contributed equally to this work.
- 20 **Keywords:** hydroxychloroguine, azithromycin, Covid-19, pneumonia
- 21 **Financial Disclosure:** The authors have no financial relationships relevant to this
- 22 article to disclose.

**Conflict of interest statement:** The authors have no specific conflict of interest. **Corresponding author:** Benjamin Davido, Service de Maladies Infectieuses et Tropicales Hôpital Raymond-Poincaré, Garches 92380, France. Tel: +33-1-47107758, e-mail: benjamin.davido@aphp.fr Abstract word count: 220/250 Body of text word count: 2100 words 

Abstract:

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Introduction: Hydroxychloroquine (HCQ) with or without azithromycin is currently still debated as a potential treatment for the COVID-19 epidemic. Some studies showed discrepant results. However, timing for the treatment initiation and its setting (inhospital or out-patient) are not consistent across studies. Methods: Monocentric retrospective study conducted from 2th March to 17th April 2020, in adults hospitalized in a tertiary hospital for COVID-19. Patients characteristics were compared between groups depending on the therapy received (HCQ/azithromycin taken ≥ 48 hours or other treatment). Outcomes were evaluated from admission, by the need for intensive care unit (ICU) support and/or death. Univariate analyses were performed using non-parametric tests and confirmed by a multiple logistic regression using Pearson correlation test. Results: Among 132 patients admitted for COVID-19 in the medicine ward, 45 received HCQ/azithromycin ≥ 48 hours, with a favorable outcome in 91.1% of cases (OR=6.2, p=0.002) versus others regimen (n=87). Groups were comparable at the baseline in terms of age, sex, comorbidities, extend in thoracic imaging, and severity. Among patients that required to be transferred to ICU (n=27) (for mechanical ventilation), median delay for transfer was 2 days (IQR 1-3). We report only 1 patient that presented an adverse event (a prolonged QT interval on EKG) that required to discontinue HCQ. Conclusion: The present study suggests a potential interest of the combination therapy using HCQ/azithromycin for the treatment of COVID-19 in in-hospital patients.

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

**Introduction:** Hydroxychloroquine (HCQ) is currently still debated as a potential treatment for the COVID-19 epidemic. In France, Gautret et al. [1,2] and Million et al. [3] showed in Marseille that a combination therapy using HCQ and azithromycin could potentially reduce viral shedding and locally flatten the epidemic curve by reducing the number of pneumonias associated with COVID-19. Although these studies are of interest considering the sample size (n>1000) they are partly conducted on outpatients and do lack a control group without HCQ and azithromycin. Concomitantly, a study conducted by Mahevas et al. [4] decided to evaluate HCQ alone (600 mg per day) prescribed in an in-hospital setting within 48 hours after admission (n=84) in comparison to standard of care, and showed no difference between groups assessed by a transfer in intensive care unit (ICU) and/or death. Those findings are concordant with a recent publication issued in United States by Magagnoli *et al.* [5] despite some bias at baseline. More, recently Esper et al. [6] in Brazil reported a potential interest of HCQ (using a loading dose of 800 mg followed by 600 mg during 6 days) plus azithromycin in the prevention of hospital admission in patients presenting compatible symptoms of COVID-19 (a 2.8-fold decrease if HCQ was administered within the first 7 days of symptoms). To our knowledge, at the time being, there is no study evaluating the interest of an administration of HCQ plus azithromycin during at least 48 hours in an in-hospital setting and its impact on the admission in intensive care unit (ICU). Since the 25<sup>th</sup> of March 2020 in France, in the context of the state of health emergency, the ministerial decree #2020-314 authorized the in-hospital prescription of HCQ for COVID-19 patients. Therefore, we decided to report our own experience of this regimen in order to draw conclusions whether we pursue such combination therapy for hospitalized patients.

# Methods:

Setting

We conducted a monocentric and retrospective study, from 2th March 2020 to 17th April 2020, regarding adults admitted in our medicine wards in a tertiary university hospital namely Hôpital Raymond Poincaré (AP-HP), Garches, France. For decades, this hospital, and particularly the ICU, is specialized in the management of neurological impairment and infectious diseases. Since the beginning of the COVID-19 outbreak, an entire building, namely Widal (in honor of Doctor Fernand Widal), was entirely dedicated to admit only COVID-19 positive patients. During the peak of the epidemic, we had a maximum capacity of 85 beds for medicine and 32 beds for ICU.

We included all the adults admitted in medicine for a COVID-19 infection confirmed by SARS-CoV-2 PCR and/or a compatible pulmonary CT-scan. Exclusion criteria were i) patients discharged from ICU to a medicine ward; ii) opposition to collect data expressed by the patient.

#### Data collection

117 The following data were collected from patient's medical charts: 118 - Patient characteristics: age, sex, diabetes, cardiovascular risk factor, smoking 119 habits, obesity, chronic pulmonary disease, Charlson comorbidity score, 120 - Infection characteristics: delay between onset of symptoms and admission, presence of super-infection, C-reactive protein (CRP) and white blood cell count 121 122 (WBC) at admission, percentage of lung injuries on CT-scan if applicable, positive 123 PCR amplifying the betacoronavirus E gene and the SARS-CoV-2 RdRp gene on 124 nasopharyngeal swab or sputum, 125 - Treatment characteristics: requiring ICU support with invasive ventilation, 126 associated therapeutic strategies (especially HCQ and azithomycin), 127 - Unfavorable outcome was evaluated after admission, by the need for ICU support 128 and/or death, 129 - The patients were followed-up until hospital discharge. 130 Treatment strategies 131 132 All patients under oxygen received systematically a beta-lactam for at least 5 days, using preferentially ceftriaxone to treat a potential super-infection. 133 134 Patients were eligible to a targeted therapy against COVID-19 considering the 135 following indications: i) patient presenting a clinical pneumonia confirmed by SARS-CoV-2 PCR requiring oxygen therapy (independently of the CT scan findings); ii) high 136

suspicion of COVID-19 pneumonia considering the clinical presentation and

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

confirmed by a pulmonary CT-scan showing ground-glass opacity affecting ≥ 10% of the whole parenchyma Before HCQ initiation, patients had systematically an EKG to evaluate the corrected QT interval using the Framingham formula, and monitored 2 times per week during 10 days. A loading dose at day 1 with 800 mg/day was administered followed by a maintenance dose of 400 mg/day up to 600 mg/day in case of obesity (body mass index (BMI) > 30) for a total 10 days. In addition, 500 mg of azithromycin was prescribed the first day, followed by 250 mg for 4 days. Patients were informed that HCQ is currently off-label for the treatment of COVID-19. In case they refused the prescription of HCQ or the latter was contraindicated, it was noted into their medical chart and patients were eligible for other therapeutic strategies. Primary objective was to evaluate whether HCQ plus azithromycin (HI-ZY-COVID) initiated after their admission was associated with a favorable outcome. For analysis purposes, we stated that patients should receive at least 48 hours of the above combination therapy to be considered effective. Therefore, patients were divided into 2 groups: the ones who received specifically HCQ/azithromycin for 48 hours or more and the remaining. Statistical analysis Quantitative variables were expressed using mean and standard deviation or median and interquartile range (IQR) when appropriate. Qualitative variables were described by percentage. Comparisons were performed using non-parametric tests with a Yates' continuity corrected chi-square test for qualitative variables and a Mann-Whitney test for quantitative variables. Multiple logistic regression test was performed using Pearson correlation test. Analyses were performed using GraphPad Prism v.8.3.1 (GraphPad Software Inc., La Jolla, CA). Statistical significance was defined for p  $\leq$  0.05.

## Compliance with Ethical Standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This cohort is registered on ClinicalTrials.gov (NCT04364698). The study was approved by the local Ethics Committee. As data used in the study were anonymous and retrospective, the requirement for informed consent was waived by the Ethics Committee.

### Results:

Overall 132 were eligible for the analysis (see flowchart in Figure 1). Forty-five patients received HCQ plus azithromycin for more than 48 hours after admission. The remaining patients (n=87) were in the others regimen group. Of note, in patients who did not receive HCQ, 5 had cardiac contraindication and 2 refused to be treated with this molecule.

Patient characteristics between HCQ/azithromycin ≥ 48 hours and the no-HCQ/azithromycin (control group) were comparable and are detailed in Table 1. It should be noted that patients receiving HCQ/azithromycin had higher need for oxygen and higher CRP level at admission than the control group.

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

For analysis purposes the cohort was divided according to the outcome into 2 groups: "favorable outcome" and "unfavorable outcome" (ICU and/or death). Main findings are summarized in Table 2. Well-known comorbidities in COVID-19 (cardiovascular, respiratory, diabetes, immune deficiency, obesity) that were similar at baseline were not associated with the outcome (p>0.2). During the course of HCQ/azithromycin, we report only 1 patient that presented an adverse event (a prolonged QT interval on EKG) without clinical event that required to discontinue HCQ before 48h, and was therefore placed in the azithromycin group. Among patients that required to be transferred to ICU (n=27) (for mechanical ventilation), median delay for transfer was 2 (1-3) days. Up to this day, 10 (37%) patients died in ICU and 2 in medical ward. For clarification, outcomes according to the rapeutic strategy are illustrated in Figure 2. Multiple logistic regression confirmed that a favorable outcome was associated with receiving HCQ plus azithromycin (p=0.009), oxygen flow (p<0.0001), lymphocyte count (p=0.002) and CRP (p=0.002) detailed in Figure 3. Discussion: Our study supports that in-hospital patients treated with HCQ plus azithromycin for more than 48 hours, have a reduced risk to be transferred to ICU and/or to decease (OR=6.2).Our findings are concordant with Gautret et al. [1,2] who revealed good clinical and virologic outcomes using this combination therapy, in the limit of the absence of a

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

control group in his study conducted especially among ambulatory care patients. Furthermore, Esper et al. [6] reported efficacy of the combination therapy of HCQ/azithromycin in outpatients exclusively. The main limit of this study is the lack of PCR testing, despite the fact the majority of patients included in the HCQ/azithromycin arm had a high rate of CT-scan lung injuries compatible with COVID-19. To support our results, we ensured that the difference accounting for the HCQ/azithromycin arm was not associated with an earlier initiation of treatment (see Table 1). Interestingly, despite the fact HCQ was initiated after a median delay of 9 days from onset of symptoms, period approaching the so-called "cytokine storm" [7,8], we can hypothesize that HCQ might have played a role in the second stage of the disease as an immune-modulator as previously described [9]. Mahevas et al. [4] studied patients hospitalized for COVID-19 as we did and showed no evidence of clinical efficacy of HCQ alone (n=84) in a retrospective and comparative study. However, we have no information if patients categorized as control group received azithromycin or a symptomatic treatment. These results' discrepancies in comparison to our findings should be discussed. First, we used a combination therapy with HCQ plus azithromycin and second our patients were considered to be treated efficiently only if they received a course of at least 48 hours of this combination therapy. However, Magagnoli et al. [5] reported, in 368 hospitalized veterans with COVID-19, a higher death rate with HCQ treatment with or without azithromycin. This study has numerous bias, including a higher lymphocytopenia (<500/mm<sup>3</sup>) and more comorbidities at baseline in the patients who received HCQ, a population exclusively composed of male, including 66% of black

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

Americans. Also, the posology of HCQ is lacking and 31% had azithromycin in the control group. Our findings are all the more remarkable, considering that patients in the HCQ/azithromycin group required significantly more oxygen (p=0.005) and had higher CRP (p=0.008) at baseline, which is deemed to be a predictive factor of severity in COVID-19 pneumonia [10]. Of note, in multivariate analysis our patients in ICU had lower lymphocyte count and higher CRP level (p=0.002) as commonly described [11]. Interestingly, patients who received azithromycin alone had a trend to a better outcome than standard of care (multivariate analysis, p=0.05), in the limit of the sample size (n<30). Azithromycin's potential antiviral activity is concordant with previous in vitro studies regarding SARS-CoV-2 [12] or H1N1-pdm09 [13] and one clinical randomized trial in in the prevention of children respiratory infections [14]. As azithromycin is commonly prescribed and authorized in ambulatory care, a study conducted among general practitioners could be relevant to evaluate this single therapy for the control of COVID-19 in outpatients. In addition, our experience confirms the safety of HCQ, without any serious side effect, as long as we take the necessary caution at the initiation of therapy and during follow-up EKG. This low risk of toxicity using a conventional dose of HCQ associated with azithromycin is concordant with Borba et al. [15]. Finally, we believe the combination using HCQ plus azithromycin is relatively costeffectiveness and makes it particularly attractive to better control the hospital overflow during the pandemic.

However, our study has several limitations. First, it is a retrospective study with a limited sample size (n=132), with a pre-established statement that considered HCQ plus azithromycin had to be received for at least 48 hours to interpret its impact. Second, groups were not balanced in terms of individuals notably because prior to the 25<sup>th</sup> of march, HCQ was not authorized by the French Minister for Solidarity and Health and drug was therefore out of stock. Third, we performed less frequently lung CT-scans in the no-HCQ/azithromycin group, partly because CT-scans were not recommended for COVID-19 at the beginning of the outbreak in our hospital (in early March). Also, in our ICU critical care physicians do not systematically perform CTscans in intubated patients considering the higher risk of contamination from those patients. Fourth, as we are facing a recent outbreak of COVID-19 in France where knowledge and criteria of ICU transfer might have changed over time and considering prolonged length of stay in ICU [16], the overall mortality might have been underestimated, as (n=6/29) are still under mechanical ventilation assistance. Finally, we can discuss our decision not to exclude patients receiving lopinavir from the control group (n=14), however there is currently no solid data supporting its efficacy against SARS-CoV-2 [17]. In conclusion, our study confirms already known risk factors for unfavorable outcomes in COVID-19 hospitalized patients. Moreover, the present work highlights the potential interest of the combination therapy of HCQ/azithromycin (≥48 hours' intake) by limiting the rate of ICU transfer. A larger and randomized controlled study is necessary to confirm those preliminary findings. Our data constitute a hope to flatten the epidemic curve and prevent ICU overflow in case of a possible second wave.

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

**Figure 1:** Flowchart of the studied population. Figure 2: Outcome pictured depending on the received therapeutic strategy. HCQ = hydroxychloroquine; AZI = azithromycin; SOC = standard of care which includes no targeted therapy, or lopinavir/r or treatment received <48h until unfavorable outcome (transfer to ICU or death). Figure 3: Factors influencing the outcome in a multiple logistic regression using a Pearson correlation test. Coefficient values can range from +1 to -1, where +1 indicates a perfect positive relationship, -1 indicates a perfect negative relationship, and a 0 indicates no relationship exists. HCQ = hydroxychloroquine; AZI = azithromycin; SOC = standard of care which includes no targeted therapy, or lopinavir/r or treatment received <48h until unfavorable outcome (transfer to ICU or death). **Acknowledgments:** First author (BD) would like to thank Azzam Saleh-Mghir for his unfailing support. **Contributors' Statement:** BD and PDT conceptualized and designed the study, carried out the initial analyses, coordinated and supervised data collection, drafted the initial manuscript, and reviewed and revised the manuscript.

- 302 BD, SB, TL, CP designed the data collection instruments, collected data and PDT
- and AD reviewed and revised the manuscript.
- All authors approved the final manuscript as submitted and agree to be accountable
- 305 for all aspects of the work in ensuring that questions related to the accuracy or
- integrity of any part of the work are appropriately investigated and resolved.

#### **List of Collaborators**

309 \**COVID-19 RPC Team* 

307

308

- 310 <u>Department of Intensive Care</u>
- 311 Djillali Annane, MD, PhD (1,2,5)
- 312 Xavier Ambrosi, MD (4)
- 313 Suzanne Amthor, MD (1)
- Rania Bounab, MD (1,2)
- 315 Ryme Chentouh, MD (1)
- 316 Bernard Clair, MD (1)
- 317 Abdallah Fayssoil, MD (1,2,5)
- 318 Diane Friedman, MD (1)
- 319 Nicholas Heming, MD, PhD (1,2,5)
- 320 Virginie Maxime, MD, (1)
- 321 Pierre Moine, MD, PhD (1,2,5)
- 322 Myriam Niel Duriez, MD (1)
- 323 David Orlikowski, MD, PhD (1,2,5,8)
- 324 Francesca Santi, MD (1,2)
- 326 Pharmacy

325

331

- 327 Frédérique Bouchand, PharmD (1)
- 328 Muriel Farcy-Afif, PharmD (1)
- 329 Hugues Michelon, PharmD, MSc (1)
- 330 Maryvonne Villart, PharmD (1)
- 332 Research Staff
- 333 Isabelle Bossard (8)
- 334 Tiphaine Barbarin Nicolier (1)
- 335 Stanislas Grassin Delyle, MCUPH (2,3,5)
- 336 Elodie Lamy (2,5)
- 337 Camille Roquencourt, MD (5)
- 338 Gabriel Saffroy (2)
- 339 Etienne Thevenot (5)

341 Department of Intensive Care Interns 342 Baptiste Abbar (1) 343 Steven Bennington (1) 344 Juliah Dray (1) 345 Pierre Gay (1) Elias Kochbati (1) 346 Majistor Luxman (1) 347 348 Myriam Moucachen (1) 349 Alice Pascault (1) 350 Juan Tamavo (1) 351 Justine Zini (1) 352 353 Department of Anesthesia, Perioperative Care, and Pain 354 Marie Boutros, MD (1) 355 Anne Lyse Bron, MD (11) Denys Coester, MD (12) 356 357 Etiennette Defouchecour, MD (11) 358 Brigitte Dosne Blachier, MD (11) 359 Léa Guichard, MD (1) Damien Hamon Pietrin, MD, PhD (1) 360 361 Hakim Khiter, MD (1) 362 Valéria Martinez, MD, PhD (1,2,6) 363 Simone Meuleye, MD (1) Suzanne Reysz, MD (1) 364 Sebastien Schitter, MD (1) 365 366 Chawki Trabelsi, MD (1) 367 368 Pediatric Critical Care Unit 369 Helge Amthor, MD, PhD (1,2,7) Jean Bergounioux MD (1,2,5) 370 371 Maud Guillon, MD (1) 372 Amal Omar, MD (1) 373 374 Laboratory of Physiology 375 Frédéric Lofaso, MD, PhD (1,2,7,10) 376 Helene Prigent, MD, PhD (1,2,7,10) 377 378 Department of Rehabilitation and Physical Medicine Diamel Bensmail, MD, PhD (1,2,7,10) 379 380 Pierre Denys, MD, PhD (1,2,7,10) 381 Charles Joussain, MD, PhD (1) 382 Lauren Kagane, MD (1) 383 Thibaut Lansaman, MD (1) 384 Hélène Le Liepvre, MD (1) 385 Antoine Leotard, MD, MS (1) Jonathan Levy, MD, MS (1,2,7,10) 386 387 Claire Malot, MD (1)

388 Julie Paquereau, MD (1) 389 Celia Rech, MD (1) 390 391 Department of Rehabilitation Interns 392 Florence Angioni (1) 393 Elsa Chkron (1) Céline Karabulut (1) 394 395 Jérôme Lemoine (1) 396 Noémie Trystram (1) 397 Julien Vibert (1) 398 399 Department of Infectious Diseases 400 Simon Bessis, MD (1,2) 401 Pascal Crenn, MD, PhD (1,2,7) Benjamin Davido, MD, MS (1) 402 403 Aurélien Dinh, MD, MS (1,2) 404 Stéphanie Landowski, MD (1) 405 Hélène Mascitti, MD, MS (1) 406 Morgan Matt, MD (1,2) 407 Christian Perronne, MD, PhD (1,2) 408 Véronique Perronne, MD (1) 409 Soline Simeon, MD, MS (1) 410 Pierre de Truchis, MD, MS (1) 411 412 Department of Infectious Diseases Interns Marc Hobeika (1) 413 414 Louis Jacob (1) 415 Nicolas Kiavue (1) 416 Aymeric Lanore (1) Aurélie Le Gal (1) 417 418 Julia Nguyen Van Thang (1) 419 420 Department of Microbiology and Innovative Biomarkers Platform 421 Coralie Favier (1) Jean Louis Gaillard, MD, PhD (1,2,5) 422 423 Elyanne Gault, MD, PhD (1,2,5) 424 Jean-Louis Herrmann, PharmD, PhD (1,2,5) 425 Christine Lawrence, PharmD (1) 426 Virginie Lebidois, PharmD (1) 427 Latifa Noussair, MD (1) Martin Rottman, MD, PhD (1,2,5) 428 429 Anne-Laure Roux, PharmD, PhD (1,2,5) 430 Sophie Tocqueville (1) Marie-Anne Welti, MD, PhD (1,2,5) 431 432 And the nonmedical staff of the Department 433 Department of Laboratory Medicine and Pharmacology 434

- 435 Jean Claude Alvarez, MD, PhD (1,2,5)
- 436 Mehdi Djebrani, PharmD (1)
- 437 Pierre-Alexandre Emmanuelli (1)
- 438 Firas Jabbour, PharmD (1)
- 439 Lotfi Lahjomri, MD (1)
- 440 Mathilde Parent, MD (1)

457

463


466


- 441 And the nonmedical staff of the Department
- 443 Department of Radiology
- 444 Amine Ammar, MD (1)
- Najete Berradja, MD (1)
- 446 Robert-Yves Carlier, MD, MS (1,2,7,14)
- 447 Annaelle Chetrit, MD (1,2)
- 448 Caroline Diffre, MD (1,2)
- 449 Myriam Edjlali, MD, PhD (1,15)
- 450 Zaki El Baz, MD (1,14)
- 451 Adrien Felter, MD (1)
- 452 Catherine Girardot, MD (1,13)
- 453 Ahmed Mekki, MD, MS (1,2)
- 454 Dominique Mompoint, MD (1)
- 455 Dominique Safa, MD (1)
- 456 Tristan Thiry, MD (1)
- 458 Department of Radiology Interns
- 459 Margot Armani (1)
- 460 Olivier de Barry (1)
- 461 Antoine Kirchner (1)
- 462 Jeffery Zhou (1)
- 464 Department of Forensic Medicine
- 465 Geoffroy Lorin de La Grandmaison MD, PhD\_(1)
- 467 Department of Forensic Medicine Intern
- 468 Kevin Mahe (1)
- 470 Affiliations
- 471 1. Hôpital Raymond Poincaré, GHU APHP, Université Paris Saclay, Garches, France
- Faculté Simone Veil Santé, Université Versailles Saint Quentin en Yvelines, Université Paris
   Saclay, Montigny-le-Bretonneux, France
- 474 3. Hôpital Foch, Suresnes, France
- 4. Centre Hospitalier Universitaire de Nantes, Nantes, France
- Université de Versailles Saint-Quentin-en-Yvelines/INSERM, Laboratory of Infection &
   Inflammation-U-1173, Montigny-le-Bretonneux, France
- 478 6. Université de Versailles Saint-Quentin-en-Yvelines/INSERM, Centre d'Evaluation et de 479 Traitement de la Douleur-U-987, Boulogne-Billancourt, France

480 7. Université de Versailles Saint-Quentin-en-Yvelines/INSERM, Handicap Neuromusculaire-U-481 1179, Montigny-le-Bretonneux, France 482 8. Centre d'Investigation Clinique, Garches, France 483 9. Commissariat à l'Energie Atomique, CEA Paris Saclay, Gif-sur-Yvette, France 484 10. Fondation Garches, Garches, France 485 11. Clinique Jouvenet, Ramsay Santé, Paris, France 12. Clinique de la Muette, Ramsay Santé, Paris, France 486 487 13. Polyclinique Mantaise, Mantes-La-Jolie, France 488 14. Centre Hospitalier Intercommunal Poissy/Saint-Germain, GHT Yvelines Nord, Poissy, France 489 15. IMA-BRAIN/INSERM—UMR-1266, DHU-Neurovasc, Centre Hospitalier Sainte-Anne, Paris, 490 France 491 492 References: 493 [1] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroguine and 494 495 azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot 496 observational study. Travel Med Infect Dis 2020:101663. doi:10.1016/j.tmaid.2020.101663. 497 [2] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. 498 499 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of 500 an open-label non-randomized clinical trial. Int J Antimicrob Agents 501 2020:105949. doi:10.1016/j.ijantimicag.2020.105949. 502 [3] Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S, et al. Early 503 treatment of 1061 COVID-19 patients with hydroxychloroguine and 504 azithromycin, Marseille, France. n.d. [4] Mahevas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. No 505 evidence of clinical efficacy of hydroxychloroguine in patients hospitalized for 506 507 COVID-19 infection with oxygen requirement: results of a study using routinely

508 collected data to emulate a target trial. MedRxiv 2020:2020.04.10.20060699. doi:10.1101/2020.04.10.20060699. 509 510 [5] Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et 511 al. Outcomes of hydroxychloroguine usage in United States veterans 512 hospitalized with Covid-19. MedRxiv 2020:2020.04.16.20065920. doi:10.1101/2020.04.16.20065920. 513 Barbosa Esper R, Souza da Silva R, Teiichi Costa Oikawa F, Machado Castro 514 [6] M, Razuk-Filho A, Benedito Batista Junior P, et al. Empirical treatment with 515 hydroxychloroguine and azithromycin for suspected cases of COVID-19 516 517 followed-up by telemedicine. n.d. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors 518 [7] for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective 519 cohort study. Lancet (London, England) 2020;395:1054-62. 520 521 doi:10.1016/S0140-6736(20)30566-3. 522 [8] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, 523 England) 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5. 524 [9] 525 Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 526 2020:105982. doi:10.1016/j.ijantimicag.2020.105982. 527 528 [10] ET, IN-S, IE, EK, TNS, MP, et al. Hematological Findings and 529 Complications of COVID-19. Am J Hematol 2020. doi:10.1002/AJH.25829. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia 530

predicts disease severity of COVID-19: a descriptive and predictive study. 531 532 Signal Transduct Target Ther 2020;5:33. doi:10.1038/s41392-020-0148-4. 533 [12] Touret F, Gilles M, Barral K, Nougairède A, Decroly E, Lamballerie X de, et al. 534 In vitro screening of a FDA approved chemical library reveals potential 535 inhibitors of SARS-CoV-2 replication. BioRxiv 2020:2020.04.03.023846. 536 doi:10.1101/2020.04.03.023846. 537 [13] DH T, R S, T H, S S, Y N, A S, et al. Azithromycin, a 15-membered Macrolide Antibiotic, Inhibits Influenza A(H1N1)pdm09 Virus Infection by Interfering With 538 Virus Internalization Process. J Antibiot (Tokyo) 2019;72. doi:10.1038/S41429-539 540 019-0204-X. 541 LB B, TW G, DT M, S B, A B, AM F, et al. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool 542 Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA 543 544 2015;314. doi:10.1001/JAMA.2015.13896. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. 545 [15] Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive 546 547 Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Netw Open 2020;3:e208857. 548 doi:10.1001/jamanetworkopen.2020.8857. 549 Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of 550 [16] Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708–20. 551 doi:10.1056/NEJMoa2002032. 552 553 [17] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of LopinavirRitonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020:NEJMoa2001282. doi:10.1056/NEJMoa2001282.





<u>Table 1:</u> Demographic and clinical characteristics at baseline

Variables	HCQ+AZI ≥ 48h	Others regimen*	p-value
	(n=45)	(n=87)	(α=0.05)
Demographic data			
Age, mean ± SD	58 ± 17	59 ± 16	0.74
Male sex – no (%)	31 (68.9)	55 (63.2)	0.65
Patients with a Charlson Comorbidity Index	7 (15.5)	23 (25.9)	0.23
(CCI) ≥ 5**, no (%)			
Comorbidities - no (%)			
<ul> <li>Cardiovascular disease (incl. HBP)</li> </ul>	17 (37.8)	40 (46.0)	0.47
<ul> <li>Chronic respiratory disease (incl. COPD)</li> </ul>	8 (17.8)	14 (16.1)	0.99
- Diabetes	7 (15.5)	18 (20.7)	0.63
<ul> <li>Chronic kidney failure</li> </ul>	1 (2.2)	3 (3.4)	0.88
<ul> <li>Chronic liver disease (≥ Child-Pugh B)</li> </ul>	0	1 (1.2)	0.73
- Immunodepression	4 (8.9)	7 (8.0)	0.86
<ul> <li>Obesity (BMI&gt; 30 kg/m²)</li> </ul>	8 (17.8)	6 (6.9)	0.1
COVID-19 data			
Median delay from onset of symptoms until	8 (6-11)	7 (4-8)	0.005
admission, (IQR) in days			
Median delay between initiation of therapeutic	9 (6-12)	7 (6-9)	0.04
strategy and onset of symptoms, (IQR) in days			
PCR COVID-19 positive – no (%)	43 (95.5)	83 (95.5)	0.99
Oxygen flow at admission, median (IQR) – L/min	2 (2-4)	2 (0-3)	0.001
Thoracic imaging			
Patients with a lung CT scan – no (%)	44 (97.8)	59 (67.8)	0.0002
Normal CT scan – no (%)	1 (2.3)	3 (5.1)	0.83
Limited extend on CT scan <10%	7 (15.9)	9 (15.3)	0.85
Mild extend on CT scan 10-25%	11 (25)	16 (27.1)	0.99
Moderate extend on CT scan 25-50%	19 (43.2)	24 (40.7)	0.96
Severe extend on CT scan 50-75%	6 (13.7)	6 (10.2)	0.81
Critical extend on CT scan >75%	0	1 (1.7)	0.88
Biological tests			
Median lymphocyte count (IQR) - /mm <sup>3</sup>	920 (710-1160)	1065 (745-1530)	0.16
Median C-reactive protein (CRP) (IQR) — mg/L	90.5 (55-152)	62 (14-106)	0.008

<sup>\*</sup>Others regimen include azithromycin (n=28), lopinavir/ritonavir (n=14) or no targeted therapy (n=36) and 9 individuals treated with HCQ plus azithromycin for less than 48 hours before transfer to ICU and/or death

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; HBP, high blood pressure

<sup>\*\*</sup>Patients with a CCI scores ≥5 are considered as severe and fragile.

<u>Table 2:</u> Risk-factors and clinical outcome of COVID-19 hospitalized patients. Variables are compared using Chi-square test with Yates' correction. Odds ratio (OR) were obtained using Baptista-Pikes method. Multiple logistic regression was performed to calculate a r correlation factor using Pearson test.

Variables	Favorable outcome n (%)	ICU or death n (%)	Univariate analysis		Multivariate analysis	
			OR (95% CI) for favorable outcome	p-value	r (95% CI) for favorable outcome	p-value
Baseline characteristics						
Age, mean ± SD	57 ± 1.6	64 ± 2.8	-	0.05	-0.32 to 0.011	0.067
Gender (% male)	68 (66)	18 (62)	-	0.82	-	=
Median delay between onset of symptoms and admission, (IQR) in days	7 (4-10)	6 (5-9)	-	0.31	-0.11 to 0.22	0.52
Median delay between initiation of therapeutics and onset of symptoms, (IQR) in days	8.5 (6-10)	7 (6-10)	-	0.29	-0.09 to 0.3	0.27
Median oxygen flow at admission						
(IQR) - L/min	2 (0-3)	3 (2-4)	-	0.003	-0.48 to -0.17	<0.0001
CT scan lung affected > 50%						
Yes	10 (76.9)	3 (23.1)				
No	76 (84.5)	14 (15.5)	1.62 (0.43 to 6)	0.78	-	=
Median lymphocyte count at admission (IQR) - /mm <sup>3</sup>	1110 (780-1450)	810 (700-955)	-	0.0005	0.1 to 0.42	0.002
Median CRP count at admission (IQR) - mg/L	62 (16-112.5)	112 (82-161.5)	-	0.001	-0.42 to -0.1	0.002
Charlson Comorbidity Index (CCI)**						
CCI <5	81 (79.4)	21 (20.6)				
CCI ≥5	22 (73.3)	8 (26.7)	0.7 (0.27 to 1.82)	0.65	-	-
Obesity (BMI> 30 kg/m²)						
Yes	13 (92.8)	1 (7.2)				
No	90 (76.3)	28 (23.7)	0.25 (0.02 to 1.46)	0.28	-0.04 to 0.29	0.15
Therapeutic data						
HCQ + azithromycin ≥ 48 hours	41 (91.1)	4 (8.9)	6.2 (2.1 to 17.6)	0.002	0.06 to 0.38	0.009
Azithromycin ≥ 48 hours	24 (92.3)	2 (7.7)	7.2 (1.76 to 33.0)	0.01	-0.0001 to 0.33	0.05
Standard of care*	38 (62.3)	23 (37.7)	1	-	1	-
Total	103	29		-		

<sup>\*</sup>standard of care includes no targeted therapy, or lopinavir/r or treatment received <48h until unfavorable outcome (transfer to ICU or death)

<sup>\*\*</sup> Patients with CCI scores ≥5 are considered as severe and fragile

